**Background of ITGB5 Antibody**
The ITGB5 antibody targets integrin beta-5 (ITGB5), a subunit of the αvβ5 heterodimeric integrin receptor. Integrins are transmembrane proteins that mediate cell-cell and cell-extracellular matrix (ECM) interactions, playing critical roles in adhesion, migration, signaling, and tissue homeostasis. ITGB5 pairs exclusively with the αv subunit to form the αvβ5 integrin, which recognizes ligands containing the RGD (Arg-Gly-Asp) motif, such as vitronectin, fibronectin, and TGF-β.
αvβ5 is implicated in diverse biological processes, including angiogenesis, wound healing, and tumor progression. It regulates cellular responses by activating signaling pathways like FAK (focal adhesion kinase) and MAPK, influencing cell survival, proliferation, and epithelial-mesenchymal transition (EMT). Dysregulation of ITGB5 expression or function has been linked to pathologies such as cancer metastasis, fibrosis, and inflammatory diseases.
ITGB5 antibodies are essential tools for studying integrin-mediated mechanisms in research applications like Western blotting, immunofluorescence, flow cytometry, and immunohistochemistry. They help elucidate αvβ5's role in disease models, evaluate its expression patterns in tissues, and explore therapeutic targeting strategies. Monoclonal and polyclonal ITGB5 antibodies are available, often validated for specificity in human, mouse, or rat samples, supporting both basic research and drug development efforts.